Yoo, S.; You, D.H.; Lee, J.; Hong, H.C.; Lee, S.J.
A Nonrandomized Phase 2 Trial of EG-Mirotin, a Novel, First-in-Class, Subcutaneously Deliverable Peptide Drug for Nonproliferative Diabetic Retinopathy. Medicina 2023, 59, 178.
https://doi.org/10.3390/medicina59010178
AMA Style
Yoo S, You DH, Lee J, Hong HC, Lee SJ.
A Nonrandomized Phase 2 Trial of EG-Mirotin, a Novel, First-in-Class, Subcutaneously Deliverable Peptide Drug for Nonproliferative Diabetic Retinopathy. Medicina. 2023; 59(1):178.
https://doi.org/10.3390/medicina59010178
Chicago/Turabian Style
Yoo, Seunghoon, Dae Hyuk You, Jeongyoon Lee, H. Christian Hong, and Sung Jin Lee.
2023. "A Nonrandomized Phase 2 Trial of EG-Mirotin, a Novel, First-in-Class, Subcutaneously Deliverable Peptide Drug for Nonproliferative Diabetic Retinopathy" Medicina 59, no. 1: 178.
https://doi.org/10.3390/medicina59010178
APA Style
Yoo, S., You, D. H., Lee, J., Hong, H. C., & Lee, S. J.
(2023). A Nonrandomized Phase 2 Trial of EG-Mirotin, a Novel, First-in-Class, Subcutaneously Deliverable Peptide Drug for Nonproliferative Diabetic Retinopathy. Medicina, 59(1), 178.
https://doi.org/10.3390/medicina59010178